ImmunityBio, Inc.

Equities

IBRX

US45256X1037

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/06/2024 BST 5-day change 1st Jan Change
7.34 USD +1.10% Intraday chart for ImmunityBio, Inc. +25.90% +46.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Mixed Thursday Afternoon MT
ImmunityBio Shares Rise After Launch of Bladder Cancer Treatment Anktiva in US MT
ImmunityBio's Bladder Cancer Treatment Anktiva Launches in US MT
ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA CI
ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment MT
ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® CI
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline MT
Immunitybio, Inc., Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin Across All Cancer Types CI
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Tuesday; MicroStrategy, Tesla to Decline MT
Piper Sandler Adjusts Price Target on ImmunityBio to $6 From $5, Maintains Neutral Rating MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Monday; Tesla, ImmunityBio to Advance MT
Transcript : ImmunityBio, Inc. - Special Call
ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer CI
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer MT
Upcoming Big Tech Earnings Buoy Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday MT
Top Premarket Gainers MT
ImmunityBio Shares Soar Premarket on FDA Nod for Anktiva DJ
US FDA approves ImmunityBio's bladder cancer therapy RE
ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer CI
U.S. FDA approves ImmunityBio's bladder cancer therapy RE
ImmunityBio Files Mixed Shelf MT
North American Morning Briefing : Markets Steady -2- DJ
Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating MT
Chart ImmunityBio, Inc.
More charts
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
7.34 USD
Average target price
7.5 USD
Spread / Average Target
+2.18%
Consensus
  1. Stock Market
  2. Equities
  3. IBRX Stock
  4. News ImmunityBio, Inc.
  5. Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Friday; ImmunityBio to Advance, Boeing to Decline